Last reviewed · How we verify
NCT03730038
Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia
NA trial testing Treatment of pitavastatin 4 mg qd for 12 weeks in Dyslipidemias in 50 participants. Completed in 13 February 2020.
13 February 2020
Quick facts
| Lead sponsor | Yonsei University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | other |
| Enrollment | 50 |
| Start date | 18 February 2019 |
| Primary completion | 13 February 2020 |
| Estimated completion | 13 February 2020 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Treatment of pitavastatin 4 mg qd for 12 weeks — full drug profile →
- Life-style modification
Conditions studied
- Dyslipidemias — all drugs for Dyslipidemias →
Sponsor
Yonsei University
Who can join
Adults 20 to 80, any sex, with Dyslipidemias. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Leucine-rich glioma inactivated 3(Lgi3) has been postulated to have a pro-inflammatory adipokine that inter-plays with other adipokines in adipogenesis and metabolic inflammation according to recent investigations. Thus, in this study, we sought to demonstrate that the treatment of statin can decrease Lgi3 level along with the decrease of the atherosclerosis to further evaluate the role of Lgi3 in atherosclerosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03730038
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dyslipidemias
Currently open trials in the same condition.
- NCT07308314 — Taining Golden Lake Comprehensive Chronic Disease Management Initiative · recruiting
- NCT06526273 — PILI 'Āina Household · NA · recruiting
- NCT06797401 — Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia · Phase 2 · recruiting
- NCT06380322 — Military Health and Nutrition Examination Study · recruiting
- NCT06183307 — Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia · NA · recruiting
Other Yonsei University trials
Trials by the same sponsor.
- NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
- NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
- NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
- NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
- NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03730038 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yonsei University
- Last refreshed: 19 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03730038.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing